LEXINGTON, Mass.--(BUSINESS WIRE)--Please replace the photo issued March 04, 2015 at 12:40 p.m. with the accompanying corrected photo.
The release reads:
QUANTERIX EXPANDS KEVIN HRUSOVSKY’S ROLE TO CEO
Life Science and Diagnostics Veteran to lead Quanterix in Driving Growth of its Disruptive Technology
Quanterix Corporation (“Quanterix”), a leader in ultrasensitive single molecule measurement for the benefit of human health, today announced the appointment of Kevin Hrusovsky as Chief Executive Officer (“CEO”). Mr. Hrusovsky will continue to serve as Executive Chairman of its Board of Directors.
“I am thrilled to have Kevin join the Quanterix team as CEO,” said Dr. David Walt, scientific founder and director of both Quanterix and Illumina. “Kevin’s experience and success with Caliper and PerkinElmer position Quanterix for scale-up to full commercialization of the transformative Simoa technology. I am excited to work with Kevin and his team to propel Quanterix to become the dominant company in ultrasensitive protein assays for both research and diagnostic applications.”
Kevin Hrusovsky brings over 20 years of experience in life science and diagnostics industries with a strong track record for innovation and commercializing disruptive technologies. Prior to joining Quanterix, he was President of Life Sciences and Technologies at PerkinElmer; CEO of Caliper Life Sciences (sold to PerkinElmer); and CEO of Zymark (sold to Caliper). Through a series of strategic acquisitions and divestitures, Mr. Hrusovsky succeeded in building substantial value, while providing researchers around the world with cutting-edge enabling tools.
“As a significant investor in Caliper (CALP), we have seen first-hand the remarkable operational, strategic and leadership strength that Kevin brings to the office of the CEO at Quanterix,” said Keith Crandell, Co-Founder and Managing Director at ARCH Venture Partners, one of the company’s lead investors. “Quanterix has by far the broadest and most powerful ultra-sensitive assay technology, and is poised for tremendous commercial growth. Under Kevin's leadership, Quanterix will fundamentally improve life sciences research and diagnostics. We are delighted that Kevin is the driving force in the commercial stage.”
Prior to PKI-CALP-Zymark, Mr. Hrusovsky was President of FMC Corporation’s Pharmaceuticals and International Agricultural Products, and held management positions at E.I. DuPont de Nemours. He currently serves on the Board of Directors of Cell Signaling, 908 Devices, SynapDX and Solect Energy.
“I am honored to be with Quanterix, and believe we are poised for compelling growth and value creation,” said Mr. Hrusovsky. “Since launching our game changing ‘bleed to read’ RUO instrument and establishing a comprehensive IVD partnership with bioMérieux, we have seen rapid growth in many different therapeutic categories demonstrating its broad potential to transform healthcare. We are excited about our team, partners, marquee founder/investors and early adopters and are increasing investment to accelerate our ascent into a world-class leader in life science and diagnostics.”
About Quanterix
Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts. To learn more about Quanterix and Simoa, please visit: www.quanterix.com
